Dr. Kaur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333
Education & Training
- University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2009 - 2012
- Government Medical College ChandigrahClass of 2004
Certifications & Licensure
- VA State Medical License 2016 - 2026
- AR State Medical License 2014 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Excellence in Clinical Care University of Virginia, Department of Medicine, 2019
- Fellow, American College of Physicians American College of Physicians, 2019
Clinical Trials
- Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer Start of enrollment: 2017 Apr 17
- Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Start of enrollment: 2018 Apr 03
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. Start of enrollment: 2019 Jan 08
- Join now to see all
Publications & Presentations
PubMed
- Fusion in Advanced Salivary Gland Carcinoma With Response to Anaplastic Lymphoma Kinase Inhibition: Case Report and Literature Review.Varinder Kaur, Sara Zadeh
WMJ. 2024-09-01 - A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma.Reema Patel, Omar Elghawy, Amanda Gibbs, Srishti Gupta, Varinder Kaur
Cancer Reports. 2024-07-01 - Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience.Omar Elghawy, Reema Patel, Adam Barsouk, Joe Puthumana, Jason Xu
Journal of Oncology Pharmacy Practice. 2024-05-05
Journal Articles
- Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act CyclesVarinder Kaur, MD, Sajjad Haider, MD, Appalanaidu Sasapu, MD, Paulette Mehta, MD, Konstantinos Arnaoutakis, MD, Issam Makhoul, MD, Journal of Oncology Practice, 10/31/2016
- PTHrP(12-48) localization is intracellular and it inhibits cell proliferation and osteoclastogenesisKaur V, Kamalakar A,Akel N, Leitzel K, Allan L, Suva LJ, Cancer Research 75(15 Supplement):1041-1041, 8/1/2015
Abstracts/Posters
- 1161 Immunotherapy (IO) associated cardiotoxicity and out-comes with re-challengeNakul Dar, Omar Elghawy, Varinder Kaur, Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
- 1468 Evaluation of safety and immunogenicity of a melanoma vaccine, with or without a systemic agonistic CD27 antibody (CDX-1127), in patients with stage II-IV melanomaFeifan Xu, Gina R Petroni, Andrew S Poklepovic, Elizabeth Gaughan, Kimberly A Chianese-Bullock, Kelly T Smith, Paul Wright, Jennifer Bryant, Craig L Slingluff, Timothy..., Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
- 1466 Phase I/II clinical trial of a melanoma vaccine targeting shared nonmutated antigens and a shared mutated neoantigen with an agonistic CD40 antibody (CDX-1140) pl...Emily K Ninmer, Gina R Petroni, Brian Gastman, Elizabeth Gaughan, James M Isaacs, Kathleen Haden, Varinder Kaur, Kimberly A Chianese-Bullock, Kelly T Smith, Paul Wrigh..., Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
- Join now to see all
Authored Content
- PARP Inhibitors As Single Agents or Combination Therapy in Melanoma: Where Do We Stand?July 2022
- Combination Immunotherapy and BRAF/MEK Inhibitor Therapy for BRAFV600-Mutated Advanced Melanoma: Are We There Yet?April 2021
Press Mentions
- Immunotherapy for the Treatment of Head and Neck CancersApril 27th, 2021
- CME Information - May 2018January 28th, 2018
- High Blood Sugar Elevates Breast Cancer RisksJune 9th, 2015
- Join now to see all
Committees
- Member, American Board of Internal Medicine Medical Oncology Item Writing Task Force 2023 - Present
- Member, American Society of Clinical Oncology Self Evaluation Program (ASCO-SEP) Medical Oncology Self-Evaluation Program 2023 - Present
- Member, ACP Virginia Chapter Governor's Advisory Council 2022 - Present
- Member, American Society of Clinical Oncology Educational Book Expert Panel 2020 - Present
- Member, ASCO Systemic Therapy for Melanom Guidelines Panel 2018 - Present
- Member, ORIEN Scientific Review Committee 2017 - Present
- Member, ASCO/ABIM Test Material Development Subcommittee 2019 - 2021
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Other Languages
- Punjabi, Hindi
External Links
- publonshttps://publons.com/author/1499975/varinder-kaur#profile
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: